Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Soticlestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 known ✓ | Q9Y6A2 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.57 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Soticlestat SCHEMBL14841089 | 1.00 | CYP46A1 (1.00) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| Soticlestat SCHEMBL31653945 | 0.99 | CYP46A1 (0.98) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| Soticlestat SCHEMBL20473188 | 0.99 | CYP46A1 (0.98) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840843 | 0.91 | CYP46A1 (0.83) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849089 | 0.88 | CYP46A1 (1.00) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL22728300 | 0.88 | CYP46A1 (0.79) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849079 | 0.88 | CYP46A1 (0.78) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840729 | 0.88 | CYP46A1 (0.78) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849088 | 0.88 | CYP46A1 (0.78) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14841024 | 0.86 | CYP46A1 (1.00) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281477-A1 | TREATMENT OF CNS CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2025-09-11 | — | — | US | claimed |
| US-20250213547-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-03 | — | — | US | claimed |
| WO-2025126159-A1 | A METHOD FOR TREATING A NEUROLOGICAL DISEASE IN A RECREATIONAL DRUG USER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-19 | — | — | WO | claimed |
| EP-4351588-A1 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Sage Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| CN-117769425-A | Neuroactive steroids for the treatment of alzheimer's disease | 萨奇治疗股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| WO-2023175591-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | WO | claimed |
| CN-116370475-A | Treatment of central nervous system disorders | 武田药品工业株式会社 | 2023-07-04 | — | — | CN | claimed |
| CN-111065394-B | Treatment of central nervous system disorders | 武田药品工业株式会社 | 2023-03-31 | — | — | CN | claimed |
| US-20230087903-A1 | TREATMENT OF CNS CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-03-23 | — | — | US | claimed |
| WO-2022261510-A1 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SAGE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| US-20220168294-A1 | TREATMENT OF CNS CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2022-06-02 | — | — | US | claimed |
| US-11285139-B2 | Treatment of CNS conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-29 | — | — | US | claimed |
| EP-4720040-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719597-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720046-A1 | SULFONAMIDE COMPOUNDS AS CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048264-A1 | SYSTEM AND METHOD FOR AFFECTING POROSITY OF TISSUE BARRIERS, INCLUDING BLOOD BRAIN BARRIER, AND DELIVERY OF ACTIVE AGENTS | REALEVE LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20220168294-A1 | TREATMENT OF CNS CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220168294-A1 | TREATMENT OF CNS CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2022-06-02 | — | — | US | disclosed |
| US-11285139-B2 | Treatment of CNS conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-29 | — | — | US | disclosed |
| US-11285139-B2 | Treatment of CNS conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168294-A1 | TREATMENT OF CNS CONDITIONS | NLN, PMP22, CYP11B2 | CYP46A1 243/4885CYP3A4 551/4885CYP2C8 764/4885 |
| US-20230087903-A1 | TREATMENT OF CNS CONDITIONS | NLN, PMP22, CYP11B2 | CYP46A1 243/4885CYP3A4 551/4885CYP2C8 764/4885 |
| US-20250281477-A1 | TREATMENT OF CNS CONDITIONS | NLN, PMP22, CYP11B2 | CYP46A1 260/4885CYP3A4 737/4885CYP2C8 899/4885 |
| US-20250213547-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES | SMN1; SMN2, PMP22, GBA2 | CYP46A1 145/4885CYP3A4 693/4885CYP2C8 1432/4885 |
| US-20260048264-A1 | SYSTEM AND METHOD FOR AFFECTING POROSITY OF TISSUE BARRIERS, INCLUDING BLOOD BRAIN BARRIER, AND DELIVERY OF ACTIVE AGENTS | PIEZO1, NGF, GAP43 | CYP46A1 3068/4885CYP3A4 2057/4885CYP2C8 1569/4885 |
| US-11285139-B2 | Treatment of CNS conditions | NLN, PMP22, CYP11B2 | CYP46A1 243/4885CYP3A4 551/4885CYP2C8 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.